Literature DB >> 32521367

Sesquiterpenoids isolated from the flower of Inula japonica as potential antitumor leads for intervention of paclitaxel-resistant non-small-cell lung cancer.

Yahui Ding1, Tianpeng Wang1, Tianyang Chen1, Chunfeng Xie2, Quan Zhang3.   

Abstract

Three new sesquiterpene lactone dimers (1-3) were isolated from the flowers of Inula japonica together with twenty-two known sesquiterpene derivatives (4-25). Their structures were established on the basis of detailed spectroscopic analyses. All isolates were evaluated for their antiproliferative activities against paclitaxel-resistant human non-small-cell lung cancer cell line A549/PTX. The preliminary structure-activity relationship was discussed. Compound 24 exhibited the most potent effect with the IC50 value of 0.34 ± 0.10 μM, even more active than the clinically used drug paclitaxel (PTX, IC50 = 1.40 ± 0.52 μM). Compound 24 showed significant efficacy of arresting the cell cycle at the G2-M stage, inducing apoptosis through mitochondria-mediated pathway, and inhibiting cell migration and invasion. Furthermore, compound 24 could reverse multidrug resistance through suppressing the expression of ABC family proteins.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Human non-small-cell lung cancer cell line; Inula japonica; Multidrug resistance; Sesquiterpene lactone dimers

Mesh:

Substances:

Year:  2020        PMID: 32521367     DOI: 10.1016/j.bioorg.2020.103973

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  2 in total

Review 1.  Japonicone A and related dimeric sesquiterpene lactones: molecular targets and mechanisms of anticancer activity.

Authors:  Christian Bailly; Gérard Vergoten
Journal:  Inflamm Res       Date:  2022-01-16       Impact factor: 4.575

2.  The Preventive Effects of Naringin and Naringenin against Paclitaxel-Induced Nephrotoxicity and Cardiotoxicity in Male Wistar Rats.

Authors:  Shimaa S Khaled; Hanan A Soliman; Mohammed Abdel-Gabbar; Noha A Ahmed; Kandil Abdel Hai Ali Attia; Hesham A Mahran; El-Shaymaa El-Nahass; Osama M Ahmed
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-30       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.